Intravenous Optison (FS069) enhances pulmonary vein flow velocity signals: a multicenter study

Area of Science:

• Cardiology
• Medical Imaging
• Echocardiography

Background:

• Pulmonary vein spectral Doppler signals are crucial for evaluating ventricular function but are often difficult to obtain.
• Intravenous contrast agents can enhance these signals, improving diagnostic capabilities.

Purpose of the Study:

• To assess the efficacy of Optison, an intravenous contrast agent, in enhancing pulmonary Doppler signals.
• To evaluate Optison's effectiveness in patients with poor signal quality during two-dimensional echocardiography.

Main Methods:

• 191 patients with inadequate pulmonary venous Doppler signals were enrolled.
• Optison was administered at varying doses (0.2, 0.5, 3.0, and 5.0 ml) to evaluate signal enhancement.
• Signal quality was assessed for both right and left pulmonary veins.

Main Results:

• The highest doses of Optison demonstrated the greatest contrast enhancement for pulmonary veins.
• At 0.5 ml, Optison converted inadequate signals to adequate in 48.0% of right and 79.3% of left pulmonary veins.
• Overall improvement in signal visualization was observed in over 54% of cases, with a low adverse event rate (6.5%).

Conclusions:

• Optison is a safe and effective contrast agent for enhancing pulmonary Doppler signals.
• The agent significantly improves the visualization of pulmonary venous flow, particularly for the left pulmonary vein.
• Optison offers a valuable tool for improving echocardiographic assessments of cardiac function.